← Research library

Vinpotropil in chronic cerebrovascular cognitive impairment

Observational study · 2010

What was studied
349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.
Main finding
The multicenter report describes improvement on repeat executive-function testing and in several self-reported symptoms after three months.

Reported findings and study design

Findings described in words

Multicenter before-and-after report in 349 patients given oral vinpocetine plus piracetam for three months.

Population or model 349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.

Dose, route and schedule

One capsule containing 5 mg vinpocetine and 400 mg piracetam, three times daily for three months.

Protocol source ↗ · Indexed English abstract of the original Russian journal report.

Results · Indexed English abstract of the original Russian journal report.
MeasureResultComparison, timing and statistics
Executive function and neurological symptomsImprovement on repeat testing and symptom ratings was reported.Three months

The abstract does not report comparative effect sizes or adverse-event counts.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The indexed abstract describes a treated cohort. It gives no independent comparator, effect sizes, arm counts or numerical adverse-event rates.

Source details

Indexed English abstract of the original Russian journal report.

Sources checked

Citation

Uncontrolled human reportEnglish abstract

V. V. Zakharov. Vinpotropil in chronic cerebrovascular cognitive impairment Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(11 Pt 1):13–16.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards